The University of Chicago Header Logo

David Kim

Concepts (198)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Cost-Benefit Analysis
32
2024
465
7.240
Why?
Health Policy
7
2024
188
2.610
Why?
Quality-Adjusted Life Years
20
2024
144
2.510
Why?
Medicare Part C
3
2022
7
2.470
Why?
Delivery of Health Care
5
2023
436
2.430
Why?
Research Design
4
2020
591
1.570
Why?
Models, Economic
5
2020
62
1.520
Why?
Policy Making
3
2020
63
1.390
Why?
Health Services Accessibility
3
2024
435
1.350
Why?
Obesity
6
2024
972
1.330
Why?
Anti-Obesity Agents
2
2024
13
1.150
Why?
Pneumonia, Viral
3
2020
319
1.110
Why?
Papillomavirus Vaccines
3
2022
58
1.100
Why?
Coronavirus Infections
3
2020
305
1.100
Why?
United States
20
2024
7080
1.090
Why?
Pandemics
3
2020
778
1.030
Why?
Health Care Costs
7
2023
236
1.010
Why?
Bariatric Surgery
2
2018
198
1.000
Why?
Obesity, Morbid
2
2018
239
0.990
Why?
Decision Making
4
2019
669
0.980
Why?
Early Detection of Cancer
4
2024
419
0.960
Why?
Deprescriptions
1
2024
6
0.950
Why?
Mass Screening
3
2022
645
0.940
Why?
Muscular Dystrophy, Duchenne
1
2024
35
0.920
Why?
Global Health
4
2021
193
0.900
Why?
Public Policy
1
2024
52
0.900
Why?
Checklist
2
2023
61
0.870
Why?
Humans
51
2024
89768
0.850
Why?
Prostatic Neoplasms
3
2024
1735
0.850
Why?
Weight Loss
1
2024
233
0.820
Why?
Cardiovascular Diseases
3
2023
715
0.820
Why?
Cost of Illness
2
2020
148
0.790
Why?
Uterine Cervical Neoplasms
2
2022
296
0.790
Why?
Nutrition Policy
3
2023
13
0.780
Why?
Papillomavirus Infections
2
2022
264
0.770
Why?
Health Facilities
1
2021
39
0.750
Why?
Communication
1
2024
461
0.720
Why?
Critical Pathways
1
2020
37
0.710
Why?
Quarantine
1
2020
8
0.700
Why?
Quality of Life
4
2024
1674
0.700
Why?
Meat Products
1
2019
7
0.680
Why?
Quality Indicators, Health Care
1
2021
149
0.680
Why?
Diabetes Mellitus
2
2023
744
0.670
Why?
Neoplasms
4
2023
3062
0.660
Why?
Clinical Trials, Phase III as Topic
1
2020
170
0.660
Why?
Clinical Trials, Phase II as Topic
1
2020
165
0.650
Why?
Physician-Patient Relations
1
2024
624
0.640
Why?
Population Health
1
2019
33
0.630
Why?
Comparative Effectiveness Research
1
2019
53
0.620
Why?
Publications
1
2018
27
0.600
Why?
Evidence-Based Practice
1
2018
48
0.600
Why?
Prostate-Specific Antigen
3
2024
338
0.550
Why?
Quality Improvement
1
2020
457
0.530
Why?
Motivation
1
2019
296
0.520
Why?
Uncertainty
4
2023
76
0.510
Why?
Insurance Coverage
3
2023
123
0.490
Why?
Patient Acceptance of Health Care
3
2024
260
0.490
Why?
Registries
5
2024
792
0.460
Why?
Nutrition Surveys
4
2023
111
0.460
Why?
Coronary Artery Disease
1
2019
364
0.450
Why?
Pancreatic Neoplasms
1
2020
683
0.450
Why?
Health Expenditures
4
2024
90
0.420
Why?
Practice Patterns, Physicians'
1
2018
607
0.420
Why?
Hepatitis C
1
2014
174
0.410
Why?
Male
12
2024
42578
0.400
Why?
Developing Countries
3
2023
80
0.390
Why?
Aged
8
2024
19209
0.370
Why?
Health Priorities
3
2020
22
0.370
Why?
Antiviral Agents
1
2014
482
0.370
Why?
Technology Assessment, Biomedical
2
2020
27
0.350
Why?
Diabetes Mellitus, Type 2
1
2018
1180
0.340
Why?
Young Adult
6
2024
6386
0.330
Why?
Female
12
2024
46491
0.330
Why?
Orphan Drug Production
2
2019
4
0.330
Why?
Cross-Sectional Studies
3
2023
1729
0.320
Why?
Adult
9
2024
26762
0.320
Why?
Middle Aged
9
2024
26076
0.280
Why?
Lung Neoplasms
1
2019
2367
0.260
Why?
Breast Neoplasms
1
2020
3021
0.260
Why?
Adolescent
4
2024
9325
0.230
Why?
Africa South of the Sahara
2
2020
23
0.220
Why?
Health Status
2
2024
371
0.220
Why?
Medicare Part D
1
2023
10
0.220
Why?
Efficiency
1
2023
40
0.210
Why?
Vaccination
2
2022
278
0.210
Why?
Incidence
2
2019
1598
0.210
Why?
Risk Factors
3
2023
5538
0.210
Why?
Drug Costs
2
2020
63
0.200
Why?
Food Labeling
1
2021
8
0.190
Why?
Psychoses, Substance-Induced
1
2020
7
0.180
Why?
Communicable Diseases, Emerging
1
2020
13
0.180
Why?
Longitudinal Studies
1
2024
1083
0.180
Why?
Marijuana Abuse
1
2020
26
0.180
Why?
Advisory Committees
1
2021
91
0.180
Why?
Age Factors
2
2022
1879
0.180
Why?
Social Conditions
1
2020
8
0.180
Why?
Actuarial Analysis
1
2020
66
0.180
Why?
Social Control, Formal
1
2020
12
0.180
Why?
Regional Medical Programs
1
2020
5
0.180
Why?
Costs and Cost Analysis
1
2020
153
0.170
Why?
Betacoronavirus
2
2020
262
0.170
Why?
Noncommunicable Diseases
1
2020
6
0.170
Why?
Insurance, Pharmaceutical Services
1
2019
3
0.170
Why?
Fear
1
2020
79
0.170
Why?
Cardiology
1
2021
115
0.170
Why?
Markov Chains
3
2014
127
0.170
Why?
Health Behavior
1
2021
185
0.170
Why?
Databases, Factual
2
2020
860
0.170
Why?
Computer Simulation
1
2024
1101
0.170
Why?
Child
2
2024
7231
0.160
Why?
Aged, 80 and over
2
2022
6777
0.160
Why?
Professional Review Organizations
1
2018
1
0.160
Why?
Probability
1
2019
350
0.160
Why?
Cost Sharing
1
2018
17
0.150
Why?
Gross Domestic Product
1
2018
2
0.150
Why?
Life Tables
1
2018
47
0.150
Why?
Disease Management
1
2020
326
0.150
Why?
Percutaneous Coronary Intervention
1
2019
66
0.150
Why?
Bibliometrics
1
2018
37
0.150
Why?
Consensus
1
2019
365
0.150
Why?
Income
1
2018
85
0.150
Why?
Research
1
2018
251
0.140
Why?
Bayes Theorem
1
2019
375
0.140
Why?
Gastrointestinal Hemorrhage
1
2019
237
0.140
Why?
Drug Prescriptions
1
2018
141
0.140
Why?
Treatment Outcome
2
2020
8240
0.140
Why?
Coronary Artery Bypass
1
2019
236
0.140
Why?
Diffusion of Innovation
1
2017
71
0.140
Why?
Proportional Hazards Models
1
2019
848
0.130
Why?
Survival Analysis
1
2019
1496
0.120
Why?
Egypt
1
2014
13
0.120
Why?
Uridine Monophosphate
1
2014
4
0.120
Why?
Sofosbuvir
1
2014
9
0.120
Why?
Surveys and Questionnaires
1
2023
2648
0.120
Why?
Decision Trees
1
2014
59
0.120
Why?
Ribavirin
1
2014
40
0.120
Why?
Body Mass Index
1
2018
775
0.120
Why?
Biomedical Research
1
2019
402
0.120
Why?
Interferons
1
2014
127
0.120
Why?
Enzyme-Linked Immunosorbent Assay
1
2014
374
0.110
Why?
Triamcinolone Acetonide
1
2013
8
0.110
Why?
Clinical Trials as Topic
1
2018
1134
0.110
Why?
Laser Coagulation
1
2013
55
0.100
Why?
Macular Edema
1
2013
50
0.100
Why?
Cohort Studies
1
2019
2886
0.100
Why?
Drug Therapy, Combination
1
2014
783
0.100
Why?
Polymerase Chain Reaction
1
2014
919
0.100
Why?
Cloprostenol
1
2012
1
0.100
Why?
Trabeculectomy
1
2012
4
0.100
Why?
Diabetic Retinopathy
1
2013
91
0.100
Why?
Glaucoma, Open-Angle
1
2012
19
0.100
Why?
Angiogenesis Inhibitors
1
2013
293
0.090
Why?
Glucocorticoids
1
2013
357
0.090
Why?
Prevalence
1
2014
1249
0.090
Why?
Disease Progression
1
2014
1466
0.090
Why?
Laser Therapy
1
2012
148
0.090
Why?
Antihypertensive Agents
1
2012
251
0.080
Why?
Tomography, X-Ray Computed
1
2019
2674
0.080
Why?
Time Factors
1
2017
5349
0.080
Why?
Insurance, Health
1
2024
164
0.050
Why?
Energy Intake
1
2023
99
0.050
Why?
Mexican Americans
1
2022
67
0.050
Why?
Dietary Sugars
1
2021
8
0.050
Why?
British Columbia
1
2020
8
0.050
Why?
Cost Savings
1
2021
70
0.050
Why?
Biopsy
1
2024
1184
0.040
Why?
Diet
1
2023
444
0.040
Why?
Cannabis
1
2020
35
0.040
Why?
China
1
2020
235
0.040
Why?
Adolescent Behavior
1
2020
109
0.040
Why?
Disabled Persons
1
2020
72
0.040
Why?
Health Planning
1
2018
17
0.040
Why?
Psychotic Disorders
1
2020
194
0.040
Why?
Health Benefit Plans, Employee
1
2018
10
0.040
Why?
Public Health
1
2020
140
0.040
Why?
Neuropsychological Tests
1
2020
508
0.040
Why?
Health Services
1
2018
57
0.040
Why?
National Cancer Institute (U.S.)
1
2018
72
0.040
Why?
Blood Pressure
1
2022
902
0.040
Why?
Global Burden of Disease
1
2018
10
0.040
Why?
Data Accuracy
1
2018
32
0.040
Why?
Disability Evaluation
1
2018
139
0.040
Why?
Program Evaluation
1
2018
312
0.030
Why?
Pilot Projects
1
2018
871
0.030
Why?
Models, Theoretical
1
2018
493
0.030
Why?
Primary Health Care
1
2018
352
0.030
Why?
Ranibizumab
1
2013
16
0.030
Why?
Diagnostic Techniques, Ophthalmological
1
2013
16
0.030
Why?
Financing, Personal
1
2013
21
0.030
Why?
Intravitreal Injections
1
2013
73
0.030
Why?
Pregnancy
1
2020
3040
0.030
Why?
Travoprost
1
2012
1
0.030
Why?
Magnetic Resonance Imaging
1
2024
3468
0.020
Why?
Bevacizumab
1
2013
268
0.020
Why?
Vascular Endothelial Growth Factor A
1
2013
405
0.020
Why?
Medication Adherence
1
2012
140
0.020
Why?
Combined Modality Therapy
1
2013
1704
0.020
Why?
Antibodies, Monoclonal, Humanized
1
2013
952
0.020
Why?
Kim's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (198)
Explore
_
Co-Authors (2)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_